Skip to main content
SpringerLink
Log in

Cannabidiol as a potential medicine

  • Chapter
Book cover Cannabinoids as Therapeutics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. ElSohly MA (2002) Chemical constituents of Cannabis. In: F Grotenhermen, E Russo (eds): Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential. Haworth Press, New York, 27–36

    Google Scholar 

  2. McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 1: 103–132

    Article  Google Scholar 

  3. Mechoulam R, Hanuš L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43

    Article  PubMed  Google Scholar 

  4. Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25: 175–213

    PubMed  Google Scholar 

  5. Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription medicines. J Cannabis Ther 1: 183–205

    Article  Google Scholar 

  6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR et al. RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161–202

    Article  PubMed  Google Scholar 

  7. Pertwee RG (2004) Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2: 9–29

    Article  Google Scholar 

  8. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: V Di Marzo (ed.): Cannabinoids. Kluwer Academic/Plenum Publishers, New York, 32–83

    Google Scholar 

  9. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S–19S

    PubMed  Google Scholar 

  10. Perez-Reyes M, Wingfield M (1974) Cannabidiol and electroencephalographic epileptic activity. J Am Med Ass 230: 1635

    Article  Google Scholar 

  11. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175–185

    PubMed  Google Scholar 

  12. Carlini EA, Leite JR, Tannhauser M, Berardi AC (1973) Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 25: 664–665

    PubMed  Google Scholar 

  13. Carlini EA, Mechoulam R, Lander N (1975) Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol 12: 1–15

    PubMed  Google Scholar 

  14. Chiu P, Olsen DM, Borys HK, Karler R, Turkanis SA (1979) The influence of cannabidiol and Δ9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 20: 365–375

    PubMed  Google Scholar 

  15. Consroe P, Wolkin A (1977) Cannabidiol — antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 201: 26–32

    PubMed  Google Scholar 

  16. Consroe P, Martin P, Eisenstein D (1977) Anticonvulsant drug antagonism of Δ9-tetrahydrocannabinol induced seizures in rabbits. Res Commun Chem Pathol Pharmacol 16: 1–13

    PubMed  Google Scholar 

  17. Consroe P, Martin A, Singh V (1981) Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol 21: 428S–436S

    PubMed  Google Scholar 

  18. Consroe P, Benedito MAC, Leite JR, Carlini EA, Mechoulam R (1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83: 293–298

    Article  PubMed  Google Scholar 

  19. Izquierdo I, Tannhauser M (1973) The effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol 25: 916–917

    PubMed  Google Scholar 

  20. Karler R, Cely W, Turkanis SA (1973) The anticonvulsant activity of cannabidiol and cannabinol. Life Sci 13: 1527–1531

    Article  PubMed  Google Scholar 

  21. Karler R, Cely W, Turkanis SA (1974) A study of the relative anticonvulsant and toxic activities of Δ9-tetrahydrocannabinol and its congeners. Res Commun Chem Pathol Pharmacol 7: 353–358

    PubMed  Google Scholar 

  22. Karler R, Cely W, Turkanis SA (1974) A study of the development of tolerance to an anticonvulsant effect of Δ9-tetrahydrocannabinol and cannabidiol. Res Commun Chem Pathol Pharmacol 9: 23–39

    PubMed  Google Scholar 

  23. Karler R, Cely W, Turkanis SA (1974) Anticonvulsant properties of Δ9-tetrahydrocannabinol and other cannabinoids. Life Sci 15: 931–947

    Article  PubMed  Google Scholar 

  24. Karler R, Turkanis SA (1980) Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 68: 479–484

    PubMed  Google Scholar 

  25. Karler R, Borys HK, Turkanis SA (1982) Influence of 22-day treatment on the anticonvulsant properties of cannabinoids. Naunyn-Schmiedeberg’s Arch Pharmacol 320: 105–109

    Article  Google Scholar 

  26. Karler R, Murphy V, Calder LD, Turkanis SA (1989) Pentylenetetrazol kindling in mice. Neuropharmacology 28: 775–780

    Article  PubMed  Google Scholar 

  27. Leite JR, Carlini EA, Lander N, Mechoulam R (1982) Anticonvulsant effects of the (−) and (+) isomers of cannabidiol and their dimethylheptyl homologs. Pharmacology 24: 141–146

    PubMed  Google Scholar 

  28. Lindamood C, Colasanti BK (1980) Effects of Δ9-tetrahydrocannabinol and cannabidiol on sodium-dependent high affinity choline uptake in the rat hippocampus. J Pharmacol Exp Ther 213: 216–221

    PubMed  Google Scholar 

  29. Martin BR, Harris LS, Dewey WL (1984) Pharmacological activity of delta-9-THC metabolites and analogs of CBD, delta-8-THC and delta-9-THC. In: S Agurell, WL Dewey and RE Willette (eds): The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Academic Press, Orlando, FL, 523–544

    Google Scholar 

  30. Turkanis SA, Cely W, Olsen DM, Karler R (1974) Anticonvulsant properties of cannabidiol. Res Commun Chem Pathol Pharmacol 8: 231–246

    PubMed  Google Scholar 

  31. Turkanis SA, Smiley KA, Borys HK, Olsen DM, Karler R (1979) An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia 20: 351–363

    PubMed  Google Scholar 

  32. Turkanis SA, Karler R (1981) Electrophysiologic properties of the cannabinoids. J Clin Pharmacol 21: 449S–463S

    PubMed  Google Scholar 

  33. Turkanis SA, Karler R (1981) Excitatory and depressant effects of Δ9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology 75: 294–298

    Article  PubMed  Google Scholar 

  34. Usami N, Okuda T, Yoshida H, Kimura T, Watanabe K, Yoshimura H, Yamamoto I (1999) Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives. Chem Pharm Bull 47: 1641–1645

    PubMed  Google Scholar 

  35. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ (2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428: 51–57

    Article  PubMed  Google Scholar 

  36. Chesher GB, Jackson DM (1974) Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacology 37: 255–264

    Article  Google Scholar 

  37. Chesher GB, Jackson DM, Malor RM (1975) Interaction of Δ9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J Pharm Pharmacol 27: 608–609

    PubMed  Google Scholar 

  38. Karler R, Turkanis SA (1979) Cannabis and epilepsy. In: GG Nahas and WDM Paton (eds): Marihuana: Biological Effects. Pergamon Press, Oxford, 619–641

    Google Scholar 

  39. Karler R, Turkanis SA (1981) The cannabinoids as potential antiepileptics. J Clin Pharmacol (suppl) 21: 437S–448S

    PubMed  Google Scholar 

  40. Karler R, Cely W, Turkanis SA (1974) Anticonvulsant activity of Δ9-tetrahydrocannabinol and its 11-hydroxy and 8α, 11-dihydroxy metabolites in the frog. Res Commun Chem Pathol Pharmacol 9: 441–452

    PubMed  Google Scholar 

  41. Banerjee SP, Snyder SH, Mechoulam R (1975) Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther 194: 74–81

    PubMed  Google Scholar 

  42. Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852

    Article  PubMed  Google Scholar 

  43. Bloom AS (1984) Effects of cannabinoids on neurotransmitter receptors in the brain. In: S Agurell, WL Dewey and RE Willette (eds): The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. Academic Press, Orlando, FL, 575–589

    Google Scholar 

  44. Bloom AS, Hillard CJ (1985) Cannabinoids, neurotransmitter receptors and brain membranes. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 217–231

    Google Scholar 

  45. Harris RA, Stokes JA (1982) Cannabinoids inhibit calcium uptake by brain synaptosomes. J Neurosci 2: 443–447

    PubMed  Google Scholar 

  46. Hershkowitz M, Goldman R, Raz A (1977) Effects of cannabinoids on neurotransmitter uptake, ATPase activity and morphology of mouse brain synaptosomes. Biochem Pharmacol 26: 1327–1331

    Article  Google Scholar 

  47. Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (™)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99–106

    Article  PubMed  Google Scholar 

  48. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1–PL6

    Article  PubMed  Google Scholar 

  49. Poddar MK, Dewey WL (1980) Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 214: 63–67

    PubMed  Google Scholar 

  50. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989–999

    PubMed  Google Scholar 

  51. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285–292

    PubMed  Google Scholar 

  52. Consroe P, Martin A, Mechoulam R (1985) Anticonvulsant effects of cannabidiol stereoisomers and analogs in rats. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 705–712

    Google Scholar 

  53. Turkanis SA, Karler R (1975) Influence of anticonvulsant cannabinoids on post tetanic potentiation of isolated Bullfrog ganglia. Life Sci 17: 569–578

    Article  PubMed  Google Scholar 

  54. Sandyk R, Consroe P, Stern L, Snider SR, Bliklen D (1988) Preliminary trial of cannabidiol in Huntington’s Disease. In: G Chesher, P Consroe and R Musty (eds): Marihuana: An International Research Report. Australian Gov. Publ. Service, Canberra, 157–162

    Google Scholar 

  55. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40: 701–708

    Article  PubMed  Google Scholar 

  56. Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30: 277–282

    PubMed  Google Scholar 

  57. Sandyk R, Snider SR, Consroe P, Elias SM (1986) Cannabidiol in dystonic movement disorders. Psychiat Res 18: 291

    Article  Google Scholar 

  58. Richter A, Löscher W (2002) Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol 454: 145–151

    Article  PubMed  Google Scholar 

  59. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effect of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82–88

    Google Scholar 

  60. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66: 175–181

    Article  PubMed  Google Scholar 

  61. Zuardi AW, Guimaraes FS, Moreira AC (1993) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian J Med Biol Res 26: 213–217

    Google Scholar 

  62. Crippa JAD, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JEC, McGuire PK, Busatto GF (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417–426

    Article  PubMed  Google Scholar 

  63. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172–177

    Article  PubMed  Google Scholar 

  64. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology 76: 245–250

    Article  Google Scholar 

  65. Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002–1009

    PubMed  Google Scholar 

  66. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100: 558–559

    PubMed  Google Scholar 

  67. Zuardi AW, Rodrigues JA, Cunha JM (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104: 260–264

    PubMed  Google Scholar 

  68. Mechoulam R, Panikashvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8: 58–61

    Article  PubMed  Google Scholar 

  69. van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JFG (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26: 317–346

    Article  PubMed  Google Scholar 

  70. Fowler CJ (2003) Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: non-psychoactive cannabinoids, ‘entourage’ compounds and inhibitors of N-acyl ethanolarnine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Rev 41: 26–43

    Article  PubMed  Google Scholar 

  71. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448–456

    Article  PubMed  Google Scholar 

  72. El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai N-J, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI (2003) Neuroprotective effect of (™)Δ9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 163: 1997–2008

    PubMed  Google Scholar 

  73. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (™)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268–8273

    Article  PubMed  Google Scholar 

  74. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000) Neuroprotective antioxidants from marijuana. In: Reactive oxygen species: from radiation to molecular biology. Annals NY Acad Sci 899: 274–282

    Google Scholar 

  75. Drysdale AJ, Pertwee RG, Platt B (2004) Modulation of calcium homeostasis by cannabidiol in primary hippocampal culture. Proc Br Pharmacol Soc at http://www.pa2online.org/VollIssue4abst052P.html

    Google Scholar 

  76. Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M (2003) Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 346: 61–64

    Article  PubMed  Google Scholar 

  77. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561–9566

    Article  PubMed  Google Scholar 

  78. Pertwee RG (2000) Neuropharmacology and therapeutic potential of cannabinoids. Addiction Biol 5: 37–46

    Article  Google Scholar 

  79. Chen Y, Buck J (2000) Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 293: 807–812

    PubMed  Google Scholar 

  80. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E (2003) Cannabidiol — transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 93: 377–387

    Article  PubMed  Google Scholar 

  81. Formukong EA, Evans AT, Evans FJ, Garland LG (1991) Inhibition of A23187-induced release of leukotriene B4 in mouse whole blood ex vivo and human polymorphonuclear cells in vitro by the cannabinoid analgesic cannabidiol. Phytotherapy Res 5: 258–261

    Google Scholar 

  82. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, Giagnoni G (2004) Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg’s Arch Pharmacol 369: 294–299

    Article  Google Scholar 

  83. Burstein S, Hunter SA, Ozman K, Renzulli L (1985) In vitro models of cannabinoid-induced pschoactivity. In: DJ Harvey (ed.): Marihuana ‘84. IRL Press, Oxford, 399–406

    Google Scholar 

  84. Formukong EA, Evans AT, Evans FJ (1988) Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12: 361–371

    Article  PubMed  Google Scholar 

  85. Sofia RD, Vassar HB, Knobloch LC (1975) Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia 40: 285–295

    Article  PubMed  Google Scholar 

  86. Evans AT, Formukong EA, Evans FJ (1987) Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem Pharmacol 36: 2035–2037

    Article  PubMed  Google Scholar 

  87. Watzl B, Scuderi P, Watson RR (1991) Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-l-alpha in vitro. Int J Immunopharmacol 13: 1091–1097

    PubMed  Google Scholar 

  88. Watzl B, Scuderi P, Watson RR (1991) Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. In: H Friedman, S Specter, TW Klein (eds): Drugs of Abuse, Immunity, and Immunodeficiency. Plenum Press, New York, Adv Exp Med Biol 288: 63–70

    Google Scholar 

  89. Burstein S, Levin E, Varanelli C (1973) Prostaglandins and cannabis — II. Biochem Pharmacol 22: 2905–2910

    Article  PubMed  Google Scholar 

  90. White HL, Tansik RL (1980) Effects of Δ9-tetrahydrocannabinol and cannabidiol on phospholipase and other enzymes regulating arachidonate metabolism. Prostaglandins and Medicine 4: 409–417

    Article  PubMed  Google Scholar 

  91. Spronck HJW, Luteijn JM, Salemink CA, Nugteren DH (1978) Inhibition of prostaglandin biosynthesis by derivatives of olivetol formed under pyrolysis of cannabidiol. Biochem Pharmacol 27: 607–608

    Article  PubMed  Google Scholar 

  92. Burstein S, Hunter SA, Ozman K (1983) Prostaglandins and Cannabis XII. The effect of cannabinoid structure on the synthesis of prostaglandins by human lung fibroblasts. Mol Pharmacol 23: 121–126

    PubMed  Google Scholar 

  93. Burstein S, Hunter SA (1978) Prostaglandins and cannabis — VI. Release of arachidonic acid from HeLa cells by Δ1-tetrahydrocannabinol and other cannabinoids. Biochem Pharmacol 27: 1275–1280

    Article  PubMed  Google Scholar 

  94. Evans AT, Formukong E, Evans FJ (1987) Activation of phospholipase A2 by cannabinoids: lack of correlation with CNS effects. FEBS Lett 211: 119–122

    Article  PubMed  Google Scholar 

  95. Srivastava MD, Srivastava BIS, Brouhard B (1998) Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacol 40: 179–185

    Article  Google Scholar 

  96. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398–1405

    PubMed  Google Scholar 

  97. Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13: 567–570

    Article  PubMed  Google Scholar 

  98. Parker LA, Mechoulam R (2003) Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci 38: 134–146

    Google Scholar 

  99. Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 10: 3769–3772

    PubMed  Google Scholar 

  100. Limebeer CL, Parker LA (2000) Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: a rat model of nausea. J Exp Psychol Anim Behav Process 26: 371–384

    Article  PubMed  Google Scholar 

  101. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171: 156–161

    Article  PubMed  Google Scholar 

  102. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174: 254–259

    PubMed  Google Scholar 

  103. Darmani NA (2002) The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachi-donoylglycerol) are blocked by Δ9-tetrahydrocannabinol and other cannnabinoids. J Pharmacol Exp Ther 300: 34–42

    Article  PubMed  Google Scholar 

  104. Colasanti BK, Brown RE, Craig CR (1984) Ocular hypotension, ocular toxicity and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 15: 479–484

    PubMed  Google Scholar 

  105. Monti JM (1977) Hypnotic-like effects of cannabidiol in the rat. Psychopharmacology 55: 263–265

    Article  PubMed  Google Scholar 

  106. Sofia RD, Knobloch LC (1976) Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol Biochem Behav 4: 591–599

    Article  PubMed  Google Scholar 

  107. Silveira Filho NG, Tufik S (1981) Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. Res Commun Psychol Psychiat Behav 6: 251–266

    Google Scholar 

  108. Murison G, Chubb CBH, Maeda S, Gemmell MA, Huberman E (1987) Cannabinoids induce incomplete maturation of cultured human leukemia cells. Proc Natl Acad Sci USA 84: 5414–5418

    PubMed  Google Scholar 

  109. Han DS, Jung KH, Jung WY, Oh IK, Kang KU, Baek SH (2000) Synthesis and cytotoxic effects of deoxy-tomentellin. Arch Pharmacol Res 23: 121–127

    Google Scholar 

  110. Jacobsson SOP, Rongård E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60: 1807–1813

    Article  PubMed  Google Scholar 

  111. Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44: 1767–1773

    Article  PubMed  Google Scholar 

  112. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838–845

    Article  PubMed  Google Scholar 

  113. Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, Mechoulam R (2004) Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 47: 3800–3806

    Article  PubMed  Google Scholar 

  114. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem 89: 134–141

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland UK

    Roger G. Pertwee

Authors
  1. Roger G. Pertwee
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Faculty, Hebrew University, Ein Kerem, Jerusalem, 91010, Israel

    Raphael Mechoulam

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Pertwee, R.G. (2005). Cannabidiol as a potential medicine. In: Mechoulam, R. (eds) Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7358-X_3

Download citation

Publish with us

Policies and ethics

Search

Navigation